Previous 10 | Next 10 |
MediWound Ltd. (MDWD) is expected to report $-0.45 for Q3 2023
2023-11-20 12:56:52 ET More on MediWound 3M to join MediWound in Phase 3 trial for wound care product MediWound burn therapy NexoBrid launched in US Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWound Financial info...
YAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 on Tuesday, November 21...
YAVNE, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine...
2023-11-08 07:45:17 ET More on MediWound 3M to join MediWound in Phase 3 trial for wound care product MediWound burn therapy NexoBrid launched in US Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWound For further de...
YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializ...
2023-10-11 06:52:44 ET More on MediWound, 3M, etc. 3M: Don't Believe It's A Value Trap? Here's Why You Should 3M: A 7%-Yielding, 30% Undervalued Dumpster Fire 3M Company Stock: At The Lows Again Industrial-stock metrics will shift from orders to organic growt...
YAVNE, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced collaboration with 3M Health Care. 3M Health Care will provide its market leading two-l...
2023-10-09 13:00:03 ET More on InMode, Nano-X, etc. Full Of Potential Red Flags: Breaking Down Nano-X Imaging Nano-X Imaging: Cash Burn Makes It A Hold InMode: Bullish Support Failed To Materialize War between Israel and Hamas pushes U.S.-traded Israeli stock...
YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in I...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...